ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1918

Cluster Analysis of Organ Involvements Patients with Serum IgG4 Elevation; IgG4–related Disease Is a Distinct Subtype of Patients with Hyper-IgG4

Masamitsu Tatewaki, Kazuhiro Kurasawa, Ayae Tanaka, Junya Nagasawa, Satoko Arai, Reika Maezawa, Takayoshi Owada and Takeshi Fukuda, Clinical Immunology, Dokkyo Medical University, Mibu, Tochigi, Japan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Clinical and IgG4

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Miscellaneous Rheumatic and Inflammatory Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose:   IgG4-related disease (IgG4-RD) is a multi-organ affecting disease characterized by fibroinflammatory lesions with a abundant IgG4-positive plasma cells infiltration. This disorder includes many conditions such as autoimmune pancreatitis, Mikulicz disease and retroperitoneal fibrosis. Elevation of serum IgG4 levels is frequently found and is a key clue for diagnosis of IgG4-RD. However, there are patents who do not have fibrotic-sclerotic lesions, characteristics of IgG4-RD, but revealed elevation of serum IgG4. To determine whether IgG4-RD is a distinct subtype of diseases with hyper-IgG4, we conducted cluster analysis of patients with elevation of serum IgG4 levels and examined clinical features of each cluster.

Methods: Subjects were 86 patients with elevation of serum IgG4 (>100mg/dl) among 350 patients whom received IgG4 examination for diagnosis of mass lesions or inflammation. Cluster analysis of organ involvements of the patients were performed through Ward’s method. Clinical features of patients in each cluster were e4xamined through reviewing medical records retrospectively.

Results: Through cluster analysis, 5 clusters were identified: cluster1; patients with multiple organ involvements including salivary glands, eyes, pancreas and retroperitoneum (typical IgG4 RD), cluster 2; patients with autoimmene pancreatitis alone (a subset of IgG4-RD), cluster 3; patients with lung involvement alone, cluster 4; patients with pleuritis alone, and cluster 5; patients without specific organ involvements. Renal involvement was found in patients in cluster1; generalized lymphadenopathy was detected in those in cluster 1, and pulmonary involvement was seen in those in cluster 1. Serum IgG4 level were significantly high in patients in cluster 1 compared to those in other clusters. In addition, serum IgG4 levels were increased in correlation with numbers of affected organs in cluster 1. Hypergammaglobulinemia occurred frequently in cluster 1. Serum CRP elevation was not found in cluster 1 and 2. IgG4 plasma cell rich infiltration was found in some biopsy samples from patients in all clusters. Glucocorticoid was effective on inflammatory lesions and systemic inflammation in most cases of all clusters.

Conclusion: Typical IgG4-RD (cluster1) is a distinct subtype of diseases with serum IgG4 elevation, which is characterized by multiple organ involvements, particularly salivary glands, eyes and retroperitoneum, generalize lymphadenopathy, marked IgG4 elevation with hypergammaglobulinemia and absence of systemic inflammation.


Disclosure:

M. Tatewaki,
None;

K. Kurasawa,
None;

A. Tanaka,
None;

J. Nagasawa,
None;

S. Arai,
None;

R. Maezawa,
None;

T. Owada,
None;

T. Fukuda,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cluster-analysis-of-organ-involvements-patients-with-serum-igg4-elevation-igg4-related-disease-is-a-distinct-subtype-of-patients-with-hyper-igg4/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology